| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1998;98:2065-2073.)
© 1998 American Heart Association, Inc.
Basic Science Reports |
Cardiac Endothelin-1 Plays a Critical Role in the Functional Deterioration of Left Ventricles During the Transition From Compensatory Hypertrophy to Congestive Heart Failure in Salt-Sensitive Hypertensive Rats
From the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Correspondence to Yasuki Kihara, MD, PhD, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. E-mail kihara{at}kuhp.kyoto-u.ac.jp
Background—To investigate whether endogenous ET-1 participates in an adaptive process of left ventricular hypertrophy (LVH) or a maladaptive process from LVH to congestive heart failure (CHF), we used a Dahl salt-sensitive (DS) rat model, in which systemic hypertension caused compensated concentric LVH at the age of 11 weeks followed by marked LV dilatation and global hypokinesis at the age of 17 weeks.
Methods and Results—By specific sandwich enzyme immunoassay,
serum and myocardial ET-1 levels at the LVH stage were not elevated
compared with age-matched Dahl salt-resistant (DR) rats,
despite the marked increase of LV/body weight ratio (LV/BW). However,
at the CHF stage, serum and LV ET-1 levels increased by 3.8-fold and
5.4-fold, respectively. LV ET-1 contents had close relationships with
the fractional shortening (r=0.763) and the
systolic wall stress (r=0.858) measured by in
vivo transthoracic echocardiography.
Immunohistochemistry demonstrated that the remarkably increased ET-1 in
LV is located mainly in cardiomyocytes. By competitive
reverse transcriptase–polymerase chain reaction, LV prepro-ET-1 mRNA
levels increased by 4.1-fold in CHF rats. We randomized 11-week-old LVH
rats to chronic treatment with the endothelin receptor
antagonist bosentan (Bos, 100 mg ·
kg-1 · d-1, n=14), the
1-receptor antagonist doxazosin (Dox, 1
mg · kg-1 · d-1, n=12), or
vehicle (Cont, n=14). Bos treatment did not alter the LV geometry and
function at 15 weeks; however, it attenuated the decrease of LV
fractional shortening by 51% (P<0.01) without reducing
the LV/BW at 17 weeks. Conversely, Dox, which decreased the blood
pressure to the same extent as Bos, did not affect the progression of
LV dysfunction. Bos (93%; P<0.0001 versus Cont) but
not Dox (42%; P=0.8465 versus Cont) ameliorated the
survival rate at 17 weeks (Cont; 36%).
Conclusions—The accelerated myocardial synthesis of ET-1 contributes directly to LV contractile dysfunction during the transition from LVH to CHF. Unelevated levels of LV ET-1 at the established LVH stage and lack of effects on LV mass by chronic bosentan treatment suggest that myocardial growth is mediated through alternative pathways. These studies indicate that chronic ET antagonism may provide an additional strategy for heart failure therapy in humans.
Key Words: endothelin • heart failure • hypertrophy • remodeling • hypertension
This article has been cited by other articles:
 |
|
 |
|
  T. Koyanagi, L. Y. Wong, K. Inagaki, O. V. Petrauskene, and D. Mochly-Rosen Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H220 - H226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takaya, T. Kawamura, T. Morimoto, K. Ono, T. Kita, A. Shimatsu, and K. Hasegawa Identification of p300-targeted Acetylated Residues in GATA4 during Hypertrophic Responses in Cardiac Myocytes J. Biol. Chem., April 11, 2008; 283(15): 9828 - 9835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rose, J. Bond, S. Tighe, M. J. Toth, T. L. Wellman, E. M. B. de Montiano, M. M. Lewinter, and K. M. Lounsbury Genes overexpressed in cerebral arteries following salt-induced hypertensive disease are regulated by angiotensin II, JunB, and CREB Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1075 - H1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kang, K. Y. Chung, and J. W. Walker G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart Physiology, June 1, 2007; 22(3): 174 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al. Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice Circulation, April 17, 2007; 115(15): 2022 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Lourenco, R. Roncon-Albuquerque Jr., C. Bras-Silva, B. Faria, J. Wieland, T. Henriques-Coelho, J. Correia-Pinto, and A. F. Leite-Moreira Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1587 - H1594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyamoto, T. Kawamura, T. Morimoto, K. Ono, H. Wada, Y. Kawase, A. Matsumori, R. Nishio, T. Kita, and K. Hasegawa Histone Acetyltransferase Activity of p300 Is Required for the Promotion of Left Ventricular Remodeling After Myocardial Infarction in Adult Mice In Vivo Circulation, February 7, 2006; 113(5): 679 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sakaguchi, K. Tambara, Y. Sakakibara, M. Ozeki, M. Yamamoto, G. Premaratne, X. Lin, K. Hasegawa, Y. Tabata, K. Nishimura, et al. Control-Released Hepatocyte Growth Factor Prevents the Progression of Heart Failure in Stroke-Prone Spontaneously Hypertensive Rats Ann. Thorac. Surg., May 1, 2005; 79(5): 1627 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dong, X. Wang, H. Zhu, F. A. Treiber, and H. Snieder Endothelin-1 Gene and Progression of Blood Pressure and Left Ventricular Mass: Longitudinal Findings in Youth Hypertension, December 1, 2004; 44(6): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Elsherif, Y. Jiang, J. T. Saari, and Y. J. Kang Dietary Copper Restriction-Induced Changes in Myocardial Gene Expression and the Effect of Copper Repletion Experimental Biology and Medicine, July 1, 2004; 229(7): 616 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Parker and J. J. Thiessen Increased endothelin-1 production in patients with chronic heart failure Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1141 - H1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Motte, R. van Beneden, J. Mottet, B. Rondelet, M. Mathieu, X. Havaux, P. Lause, C. Clercx, J.-M. Ketelslegers, R. Naeije, et al. Early activation of cardiac and renal endothelin systems in experimental heart failure Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2482 - H2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Izumi, Y. Kihara, N. Sarai, T. Yoneda, Y. Iwanaga, K. Inagaki, Y. Onozawa, H. Takenaka, T. Kita, and A. Noma Reinduction of T-Type Calcium Channels by Endothelin-1 in Failing Hearts In Vivo and in Adult Rat Ventricular Myocytes In Vitro Circulation, November 18, 2003; 108(20): 2530 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Noguchi, Z. Chen, S. P. Bell, L. Nyland, and M. M. LeWinter Endothelin receptor blockade has an oxygen-saving effect in Dahl salt-sensitive rats with heart failure Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1428 - H1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Westfall and A. R. Borton Role of Troponin I Phosphorylation in Protein Kinase C-mediated Enhanced Contractile Performance of Rat Myocytes J. Biol. Chem., September 5, 2003; 278(36): 33694 - 33700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mohri, N. Emoto, H. Nonaka, H. Fukuya, K. Yagita, H. Okamura, and M. Yokoyama Alterations of Circadian Expressions of Clock Genes in Dahl Salt-Sensitive Rats Fed a High-Salt Diet Hypertension, August 1, 2003; 42(2): 189 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sato, H. Yaoita, K. Maehara, and Y. Maruyama Attenuation of heart failure due to coronary stenosis by ACE inhibitor and angiotensin receptor blocker Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H359 - H368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishikimi, K. Tadokoro, Y. Mori, X. Wang, K. Akimoto, F. Yoshihara, N. Minamino, K. Kangawa, and H. Matsuoka Ventricular Adrenomedullin System in the Transition From LVH to Heart Failure in Rats Hypertension, March 1, 2003; 41(3): 512 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Noguchi, Y. Kihara, K. J. Begin, J. A. Gorga, K. A. Palmiter, M. M. LeWinter, and P. VanBuren Altered Myocardial Thin-Filament Function in the Failing Dahl Salt-Sensitive Rat Heart: Amelioration by Endothelin Blockade Circulation, February 4, 2003; 107(4): 630 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Brutsaert Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity Physiol Rev, January 1, 2003; 83(1): 59 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zolk, J. Quattek, U. Seeland, A. El-Armouche, T. Eschenhagen, and M. Bohm Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats Cardiovasc Res, February 1, 2002; 53(2): 363 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Clozel, C. Qiu, C.-S. Qiu, P. Hess, and J.-P. Clozel Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction J. Am. Coll. Cardiol., January 2, 2002; 39(1): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Iwai-Kanai, K. Hasegawa, T. Sawamura, M. Fujita, T. Yanazume, S. Toyokuni, S. Adachi, Y. Kihara, and S. Sasayama Activation of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Induces Apoptosis in Cultured Neonatal Rat Cardiac Myocytes Circulation, December 11, 2001; 104(24): 2948 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. J. Leeuwenburgh, W. A. Helbing, P. Steendijk, P. H. Schoof, and J. Baan Biventricular systolic function in young lambs subject to chronic systemic right ventricular pressure overload Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2697 - H2704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwanaga, Y. Kihara, K. Inagaki, Y. Onozawa, T. Yoneda, K. Kataoka, and S. Sasayama Differential Effects of Angiotensin II Versus Endothelin-1 Inhibitions in Hypertrophic Left Ventricular Myocardium During Transition to Heart Failure Circulation, July 31, 2001; 104(5): 606 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suzuki and T. Miyauchi A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1399 - R1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, M. Yoshiyama, Y. Izumi, H. Kawano, M. Kimoto, Y. Zhan, and H. Iwao Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure Circulation, January 2, 2001; 103(1): 148 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Shen, P. S Buie, J. J Lynch, S. M Krause, and X.-L. Ma Chronic therapy with an ETA/B receptor antagonist in conscious dogs during progression of congestive heart failure: Intracellular Ca2+ regulation and nitric oxide mediated coronary relaxation Cardiovasc Res, November 1, 2000; 48(2): 332 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Araki, K. Hasegawa, E. Iwai-Kanai, M. Fujita, T. Sawamura, T. Kakita, H. Wada, T. Morimoto, and S. Sasayama Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1411 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rothermund, Y. M. Pinto, B. Hocher, R. Vetter, S. Leggewie, P. Ko{beta}mehl, H.-D. Orzechowski, R. Kreutz, and M. Paul Cardiac Endothelin System Impairs Left Ventricular Function in Renin-Dependent Hypertension via Decreased Sarcoplasmic Reticulum Ca2+ Uptake Circulation, September 26, 2000; 102(13): 1582 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwanaga, Y. Kihara, T. Yoneda, T. Aoyama, and S. Sasayama Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction J. Am. Coll. Cardiol., August 1, 2000; 36(2): 635 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, T. Masuyama, Y. Sakata, T. Mano, N. Nishikawa, H. Kondo, N. Akehi, T. Kuzuya, T. Miwa, and M. Hori Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts Cardiovasc Res, August 1, 2000; 47(2): 274 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sakai, T. Miyauchi, and I. Yamaguchi Long-Term Endothelin Receptor Antagonist Administration Improves Alterations in Expression of Various Cardiac Genes in Failing Myocardium of Rats With Heart Failure Circulation, June 20, 2000; 101(24): 2849 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, T. Masuyama, Y. Sakata, R. Doi, K. Ono, T. Mano, H. Kondo, T. Kuzuya, T. Miwa, and M. Hori Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system Cardiovasc Res, June 1, 2000; 46(3): 421 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lepailleur-Enouf, O. Valdenaire, M. Philippe, M. Jandrot-Perrus, and J.-B. Michel Thrombin induces endothelin expression in arterial smooth muscle cells Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1606 - H1612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Morimoto, K. Hasegawa, S. Kaburagi, T. Kakita, H. Wada, T. Yanazume, and S. Sasayama Phosphorylation of GATA-4 Is Involved in alpha 1-Adrenergic Agonist-responsive Transcription of the Endothelin-1 Gene in Cardiac Myocytes J. Biol. Chem., April 28, 2000; 275(18): 13721 - 13726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. FINK, S. ERGÜN, D. KRALISCH, U. REMMERS, J. WEIL, and T. ESCHENHAGEN Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement FASEB J, April 1, 2000; 14(5): 669 - 679. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. MacCarthy, R. Grocott-Mason, B. D. Prendergast, and A. M. Shah Contrasting Inotropic Effects of Endogenous Endothelin in the Normal and Failing Human Heart : Studies With an Intracoronary ETA Receptor Antagonist Circulation, January 18, 2000; 101(2): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mishima, M. Tanimura, G. Suzuki, A. Todor, V. G. Sharov, S. Goldstein, and H. N. Sabbah Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure J. Am. Coll. Cardiol., January 1, 2000; 35(1): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ono, A. Matsumori, T. Shioi, Y. Furukawa, and S. Sasayama Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis : Acute Effects of Bosentan, an Endothelin Receptor Antagonist Circulation, October 26, 1999; 100(17): 1823 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin Role of Endothelin-1 in Hypertension Hypertension, October 1, 1999; 34(4): 876 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sasayama, A. Matsumori, and Y. Kihara New insights into the pathophysiological role for cytokines in heart failure Cardiovasc Res, June 1, 1999; 42(3): 557 - 564. [Full Text] [PDF]
|
|
|
|
|
|
T. Morimoto, K. Hasegawa, H. Wada, T. Kakita, S. Kaburagi, T. Yanazume, and S. Sasayama Calcineurin-GATA4 Pathway Is Involved in beta -Adrenergic Agonist-responsive Endothelin-1 Transcription in Cardiac Myocytes J. Biol. Chem., September 7, 2001; 276(37): 34983 - 34989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kakita, K. Hasegawa, E. Iwai-Kanai, S. Adachi, T. Morimoto, H. Wada, T. Kawamura, T. Yanazume, and S. Sasayama Calcineurin Pathway Is Required for Endothelin-1-Mediated Protection Against Oxidant Stress-Induced Apoptosis in Cardiac Myocytes Circ. Res., June 22, 2001; 88(12): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|